JP2018514564A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018514564A5 JP2018514564A5 JP2017556853A JP2017556853A JP2018514564A5 JP 2018514564 A5 JP2018514564 A5 JP 2018514564A5 JP 2017556853 A JP2017556853 A JP 2017556853A JP 2017556853 A JP2017556853 A JP 2017556853A JP 2018514564 A5 JP2018514564 A5 JP 2018514564A5
- Authority
- JP
- Japan
- Prior art keywords
- powder
- zolmitriptan
- particles
- powder formulation
- phosphatidyl choline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 claims 47
- 239000000203 mixture Substances 0.000 claims 35
- 238000009472 formulation Methods 0.000 claims 20
- 239000002245 particle Substances 0.000 claims 19
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N Zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 claims 16
- 229960001360 zolmitriptan Drugs 0.000 claims 16
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 13
- 239000011780 sodium chloride Substances 0.000 claims 11
- 235000002639 sodium chloride Nutrition 0.000 claims 11
- KILNVBDSWZSGLL-KXQOOQHDSA-N Dipalmitoylphosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 9
- 229960003136 leucine Drugs 0.000 claims 7
- 239000004395 L-leucine Substances 0.000 claims 6
- 235000019454 L-leucine Nutrition 0.000 claims 6
- 150000003904 phospholipids Chemical class 0.000 claims 6
- 229960002668 sodium chloride Drugs 0.000 claims 6
- 239000007787 solid Substances 0.000 claims 6
- 235000001014 amino acid Nutrition 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- 230000002685 pulmonary Effects 0.000 claims 3
- 239000005913 Maltodextrin Substances 0.000 claims 2
- 229920002774 Maltodextrin Polymers 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 229940035034 maltodextrin Drugs 0.000 claims 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
- 210000002345 respiratory system Anatomy 0.000 claims 2
- -1 sugar alcohols Chemical class 0.000 claims 2
- IJFVSSZAOYLHEE-SSEXGKCCSA-O 1,2-dilauroyl-sn-glycero-3-phosphocholine(1+) Chemical compound CCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCC IJFVSSZAOYLHEE-SSEXGKCCSA-O 0.000 claims 1
- 230000037275 AUC 0-24 Effects 0.000 claims 1
- 229960003767 Alanine Drugs 0.000 claims 1
- 208000006561 Cluster Headache Diseases 0.000 claims 1
- 230000037242 Cmax Effects 0.000 claims 1
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 229960002449 Glycine Drugs 0.000 claims 1
- 229960000310 ISOLEUCINE Drugs 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 claims 1
- 210000004072 Lung Anatomy 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 206010027599 Migraine Diseases 0.000 claims 1
- 208000008085 Migraine Disorders Diseases 0.000 claims 1
- 206010027603 Migraine headache Diseases 0.000 claims 1
- 229960005190 Phenylalanine Drugs 0.000 claims 1
- 229940067631 Phospholipids Drugs 0.000 claims 1
- 229940005581 Sodium Lactate Drugs 0.000 claims 1
- NGSFWBMYFKHRBD-UHFFFAOYSA-M Sodium lactate Chemical compound [Na+].CC(O)C([O-])=O NGSFWBMYFKHRBD-UHFFFAOYSA-M 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims 1
- 230000001058 adult Effects 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000010419 fine particle Substances 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 150000002337 glycosamines Chemical class 0.000 claims 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
- 239000008101 lactose Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 150000008105 phosphatidylcholines Chemical class 0.000 claims 1
- 239000001103 potassium chloride Substances 0.000 claims 1
- 235000011164 potassium chloride Nutrition 0.000 claims 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000001509 sodium citrate Substances 0.000 claims 1
- 239000001540 sodium lactate Substances 0.000 claims 1
- 235000011088 sodium lactate Nutrition 0.000 claims 1
- 239000011778 trisodium citrate Substances 0.000 claims 1
- 235000019263 trisodium citrate Nutrition 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
- 229960004295 valine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562155910P | 2015-05-01 | 2015-05-01 | |
| US62/155,910 | 2015-05-01 | ||
| PCT/US2016/030219 WO2016179026A1 (en) | 2015-05-01 | 2016-04-29 | Zolmitriptan powders for pulmonary delivery |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018514564A JP2018514564A (ja) | 2018-06-07 |
| JP2018514564A5 true JP2018514564A5 (US07981874-20110719-C00313.png) | 2019-06-06 |
Family
ID=56027187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017556853A Pending JP2018514564A (ja) | 2015-05-01 | 2016-04-29 | 肺送達用のゾルミトリプタン粉末 |
Country Status (9)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3316865A4 (en) * | 2015-07-02 | 2019-01-23 | Civitas Therapeutics, Inc. | POWDERS CONTAINING TRIPTAN, FOR PULMONARY DELIVERY |
| MX2020006633A (es) * | 2017-12-21 | 2021-01-15 | Civitas Therapeutics Inc | Formulaciones de surfactantes para inhalacion. |
| EP3880172A1 (en) * | 2018-11-13 | 2021-09-22 | Civitas Therapeutics, Inc. | Respirable polynucleotide powder formulations for inhalation |
| SI3962455T1 (sl) | 2020-05-18 | 2022-11-30 | Orexo Ab | Nov farmacevtski sestavek za dostavo zdravil |
| EP4236921A1 (en) | 2021-11-25 | 2023-09-06 | Orexo AB | Pharmaceutical composition comprising adrenaline |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6613308B2 (en) * | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
| US6766799B2 (en) | 2001-04-16 | 2004-07-27 | Advanced Inhalation Research, Inc. | Inhalation device |
| US6848197B2 (en) | 2001-04-18 | 2005-02-01 | Advanced Inhalation Research, Inc. | Control of process humidity to produce large, porous particles |
| JP2005520843A (ja) * | 2002-03-20 | 2005-07-14 | アドバンスト インハレーション リサーチ，インコーポレイテッド | 呼吸用持続性治療製剤 |
| US7763280B2 (en) | 2002-11-28 | 2010-07-27 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tiotropium containing powder formulation for inhalation |
| WO2008156586A2 (en) | 2007-06-12 | 2008-12-24 | Alkermes, Inc. | Inhalation device for powdered substances |
| CA2728808A1 (en) * | 2008-02-01 | 2009-08-06 | Vectura Limited | Pulmonary formulations of triptans |
| AU2011326529B2 (en) * | 2010-11-09 | 2015-07-30 | Mannkind Corporation | Composition comprising a serotonin receptor agonist and a diketopiperazine for treating migraines |
| ITMI20130572A1 (it) * | 2013-04-10 | 2014-10-11 | Eratech Srl | Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione |
-
2016
- 2016-04-29 MX MX2017013950A patent/MX2017013950A/es unknown
- 2016-04-29 CA CA2984339A patent/CA2984339A1/en not_active Abandoned
- 2016-04-29 WO PCT/US2016/030219 patent/WO2016179026A1/en active Application Filing
- 2016-04-29 KR KR1020177034671A patent/KR20180002750A/ko unknown
- 2016-04-29 US US15/143,131 patent/US20160317503A1/en not_active Abandoned
- 2016-04-29 EP EP16724183.5A patent/EP3288591A1/en not_active Withdrawn
- 2016-04-29 AU AU2016257729A patent/AU2016257729A1/en not_active Abandoned
- 2016-04-29 JP JP2017556853A patent/JP2018514564A/ja active Pending
-
2018
- 2018-09-04 HK HK18111327.1A patent/HK1251998A1/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018514564A5 (US07981874-20110719-C00313.png) | ||
| JP6806740B2 (ja) | 肺機能を改善するためならびに放射線誘発肺合併症の予防および／または処置のための物質および方法 | |
| Geller et al. | Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology | |
| ES2708218T3 (es) | Método y formulación para inhalación | |
| JP6154803B2 (ja) | 膣投与のための迅速溶解性錠剤組成物 | |
| JP2023521051A (ja) | １’－シアノ置換カルバヌクレオシド類似体の吸入製剤 | |
| JP2012517987A5 (ja) | 吸入用の医薬組成物のｆｐｄ特性を設定する方法 | |
| ES2525163T3 (es) | Método para preparar composiciones farmacéuticas pretendidas para administración oral que comprenden uno o más ingredientes activos y las composiciones que comprenden los mismos | |
| US20170007571A1 (en) | Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI) | |
| DK2698147T3 (en) | Oral film formulation with dapoxetine tadalafil | |
| PT1296663E (pt) | Administração altamente eficaz de um aerosol de grande massa terapêutica | |
| JP2015509788A5 (US07981874-20110719-C00313.png) | ||
| JP2013536845A5 (US07981874-20110719-C00313.png) | ||
| JP7021078B2 (ja) | ニコチンをベースとする乾燥粉末製剤のきつさを制御するためのシステムおよび方法 | |
| JP6316422B2 (ja) | フィンゴリモドの医薬組成物 | |
| US20130098357A1 (en) | Cerivastatin to treat pulmonary disorders | |
| JP2012522011A5 (US07981874-20110719-C00313.png) | ||
| JP7277490B2 (ja) | 肺送達用ラパマイシン粉末 | |
| JP2016532672A5 (US07981874-20110719-C00313.png) | ||
| JP2008501034A5 (US07981874-20110719-C00313.png) | ||
| JP2010503731A5 (US07981874-20110719-C00313.png) | ||
| JP2010513237A (ja) | バルガンシクロビルの粉末製剤 | |
| Zillen et al. | Natural and bioinspired excipients for dry powder inhalation formulations | |
| WO2016142708A2 (en) | Pharmaceutical composition | |
| JP2023171770A (ja) | クロファジミンの吸入可能な組成物およびその使用方法 |
